PainChek Ltd (AU:PCK) has released an update.
PainChek Ltd has reported a 6% quarterly and 36% annual increase in global licenses, now totaling 95,000, with an annual recurring revenue (ARR) of $4.6M once fully implemented. The company has also successfully completed a US FDA clinical study, setting the stage for a potential market entry with its pain assessment application into the North American market. Additionally, PainChek is gearing up for the Australian launch of its PainChek Infant App, targeting a new global market of 150 million newborns annually.
For further insights into AU:PCK stock, check out TipRanks’ Stock Analysis page.
